PMID- 37774485 OWN - NLM STAT- MEDLINE DCOM- 20231101 LR - 20231101 IS - 1878-1705 (Electronic) IS - 1567-5769 (Linking) VI - 124 IP - Pt B DP - 2023 Nov TI - Peroxisome proliferator-activated receptor gamma agonist pioglitazone alleviates hemorrhage-induced thalamic pain and neuroinflammation. PG - 110991 LID - S1567-5769(23)01316-4 [pii] LID - 10.1016/j.intimp.2023.110991 [doi] AB - BACKGROUND: Thalamic pain frequently occurs after stroke and is a challenging clinical issue. However, the mechanisms underlying thalamic pain remain unclear. Neuroinflammation is a key determining factor in the occurrence and maintenance of hemorrhage-induced thalamic pain. Pioglitazone is an agonist of peroxisome proliferator-activated receptor gamma (PPARgamma) and shows anti-inflammatory effects in multiple diseases. The present work focused on exploring whether PPARgamma is related to hemorrhage-induced thalamic pain. METHODS: Immunostaining was conducted to analyze the cellular localization of PPARgamma and co-localization was evaluated with NeuN, ionized calcium-binding adapter molecular 1 (IBA1), and glia fibrillary acidic protein (GFAP). Western blot analyses were used to evaluate MyD88, pNF-kappaB/NF-kappaB, pSTAT6/STAT6, IL-1beta, TNF-alpha, iNOS, Arg-1, IL-4, IL-6, and IL-10 expression. Behavioral tests in mice were conducted to evaluate continuous pain hypersensitivity. RESULTS: We found that pioglitazone appeared to mitigate the contralateral hemorrhage-induced thalamic pain while inhibiting inflammatory responses. Additionally, Pioglitazone induced phosphorylation of STAT6 and suppressed the phosphorylation NF-kappaB in our model of thalamic pain. These effects could be partially reversed with the PPARgamma antagonist GW9662. CONCLUSION: The PPARgamma agonist pioglitazone can mitigate mechanical allodynia by suppressing the NF-kappaB inflammasome while activating the STAT6 signal pathway, which are well-known to be associated with inflammation. CI - Copyright (c) 2023 Elsevier B.V. All rights reserved. FAU - Li, Da AU - Li D AD - Department of Anesthesiology, Pain and Perioperative Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, People's Republic of China; Henan Province International Joint Laboratory of Pain, Cognition and Emotion, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, People's Republic of China. FAU - He, Long AU - He L AD - Department of Anesthesiology, Pain and Perioperative Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, People's Republic of China; Henan Province International Joint Laboratory of Pain, Cognition and Emotion, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, People's Republic of China. FAU - Yuan, Chang AU - Yuan C AD - Department of Anesthesiology, Pain and Perioperative Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, People's Republic of China; Henan Province International Joint Laboratory of Pain, Cognition and Emotion, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, People's Republic of China. FAU - Ai, Yanqiu AU - Ai Y AD - Department of Anesthesiology, Pain and Perioperative Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, People's Republic of China; Henan Province International Joint Laboratory of Pain, Cognition and Emotion, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, People's Republic of China. Electronic address: aiyanqiu82@163.com. FAU - Yang, Jian-Jun AU - Yang JJ AD - Department of Anesthesiology, Pain and Perioperative Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, People's Republic of China; Henan Province International Joint Laboratory of Pain, Cognition and Emotion, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, People's Republic of China. Electronic address: yjyangjj@126.com. LA - eng PT - Journal Article DEP - 20230927 PL - Netherlands TA - Int Immunopharmacol JT - International immunopharmacology JID - 100965259 RN - X4OV71U42S (Pioglitazone) RN - 0 (PPAR gamma) RN - 0 (Thiazolidinediones) RN - 0 (NF-kappa B) RN - 0 (PPAR-gamma Agonists) SB - IM MH - Mice MH - Animals MH - Pioglitazone/therapeutic use MH - *PPAR gamma/metabolism MH - *Thiazolidinediones/therapeutic use/pharmacology MH - NF-kappa B/metabolism MH - Neuroinflammatory Diseases MH - PPAR-gamma Agonists MH - Hemorrhage MH - Pain/drug therapy OTO - NOTNLM OT - Hemorrhage OT - NF-kappaB OT - PPARgamma OT - STAT6 OT - Thalamic pain COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/09/30 09:42 MHDA- 2023/11/01 12:45 CRDT- 2023/09/29 18:03 PHST- 2023/06/15 00:00 [received] PHST- 2023/09/05 00:00 [revised] PHST- 2023/09/22 00:00 [accepted] PHST- 2023/11/01 12:45 [medline] PHST- 2023/09/30 09:42 [pubmed] PHST- 2023/09/29 18:03 [entrez] AID - S1567-5769(23)01316-4 [pii] AID - 10.1016/j.intimp.2023.110991 [doi] PST - ppublish SO - Int Immunopharmacol. 2023 Nov;124(Pt B):110991. doi: 10.1016/j.intimp.2023.110991. Epub 2023 Sep 27.